EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Future Directions in the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency

Kyriakie Sarafoglou iD, Richard J Auchus iD

The Journal of Clinical Endocrinology & Metabolism · 21.01.2025 · 110 (Supplement_1) · S74-S87

DOI: 10.1210/clinem/dgae759 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 21.01.2025. Verfasst von Kyriakie Sarafoglou und 1 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Pediatrics, Divisions of Pediatric Endocrinology and Genetics & Metabolism, University of Minnesota Medical School, Minneapolis, MN 55…. Hauptthemen laut MEDLINE: Adrenal Hyperplasia, Congenital. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

The traditional management of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21OHD) is difficult and often suboptimal.

Objective

To review improvements in the diagnosis and management of 21OHD.

Design

Literature review, synthesis, and authors’ experience.

Setting

United States (2 centers).

Participants

Not applicable.

Interventions

Not applicable. Main Outcomes Not applicable.

Results

The 11-oxygenated androgens are abundant in 21OHD, and their measurement might improve diagnosis and medication titration. Several new treatments are under development.

Conclusion

Circadian delivery of hydrocortisone improves disease management of 21OHD compared to conventional glucocorticoids. Glucocorticoid-sparing therapies such as crinecerfont and atumelnant offer the potential for a block-and-replace strategy, with physiologic replacement dosing of hydrocortisone. Clinical Trial Registration None.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenal Hyperplasia, CongenitalHumansHydrocortisoneGlucocorticoidsSteroid 21-Hydroxylase

Stichwörter der Autor:innen

11-ketotestosterone21-hydroxylase deficiencycongenital adrenal hyperplasiacrinecerfontdrug therapyhydrocortisone

Substanzen

HydrocortisoneGlucocorticoidsSteroid 21-Hydroxylase

Autor:innen und Institutionen

  • Departments of Pediatrics, Divisions of Pediatric Endocrinology and Genetics & Metabolism, University of Minnesota Medical School, Minneapolis, MN 55454, USA.
  • Department of Experimental and Clinical Pharmacology, University of Minnesota School of Pharmacy, Minneapolis, MN 55455, USA.
  • Departments of Pharmacology and Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
  • LTC Charles S. Kettles Veterans Affairs Medical Center, Ann Arbor, MI 48105, USA.

ORCID-Profile: Kyriakie Sarafoglou, Richard J Auchus

Zitieren

APA

Sarafoglou, K., & Auchus, R. J. (2025). Future Directions in the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. The Journal of Clinical Endocrinology & Metabolism, 110(Supplement_1), S74-S87. https://doi.org/10.1210/clinem/dgae759

Vancouver

Sarafoglou K, Auchus RJ. Future Directions in the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. The Journal of Clinical Endocrinology & Metabolism. 2025;110(Supplement_1):S74-S87. doi:10.1210/clinem/dgae759

BibTeX
@article{Sarafoglou2025,
  author = {Sarafoglou, Kyriakie and Auchus, Richard J},
  title = {Future Directions in the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  volume = {110},
  number = {Supplement_1},
  pages = {S74--S87},
  doi = {10.1210/clinem/dgae759}
}
Kostenlos starten →